Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Personlig ultraljudstimulering för depression (R61)

1 november 2026 uppdaterad av: Brian Mickey

Personlig ultraljudstimulering för depression: En studie av målengagemang och humöreffekter

This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.

Studieöversikt

Detaljerad beskrivning

This R61 project has 3 aims:

  1. To determine whether stimulation engages the subcallosal cingulate (SCC) in an intensity-dependent manner
  2. To examine the degree of specificity of neuromodulation by contrasting the neural effects of stimulating two spatially distinct targets versus sham
  3. To evaluate safety, tolerability, and side effects

Studietyp

Interventionell

Inskrivning (Faktisk)

39

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84108
        • University of Utah

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age 18-65, any gender.
  2. Primary diagnosis of DMS-5 major depressive disorder (MINI).
  3. Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).
  4. Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score > 10.
  5. History of at least 2 failed trials of evidence-based antidepressant medication and/or psychotherapy (at least one trial during the current depressive episode).
  6. Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.
  7. For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.
  8. Capacity to provide informed consent; provision of a signed and dated consent form
  9. Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.
  10. Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.
  11. Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.

Exclusion Criteria:

  1. History of serious brain injury or other neurologic disorder.
  2. Poorly managed general medical condition.
  3. Pregnant or breast feeding.
  4. Implanted device in the head or neck.
  5. MRI intolerance or contraindication.
  6. Brain stimulation treatment such as ECT, TMS, or VNS (past month).
  7. Recent change in antidepressant treatments (past month).
  8. 8. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and/or in the clinical judgement of the PI or a study psychiatrist
  9. Suicidal behavior (past year).
  10. Serious suicide attempt 33 (lifetime).
  11. Moderate-to-severe substance use disorder (MINI, past 3 months).
  12. Obsessive compulsive disorder, primary diagnosis (MINI, past month).
  13. Posttraumatic stress disorder, primary diagnosis (MINI, past month).
  14. Bipolar-spectrum disorder (MINI, lifetime).
  15. Schizophrenia-spectrum disorder (MINI, lifetime).
  16. Neurocognitive disorder (DSM-5, past year).
  17. Severe personality disorder.
  18. Clinically inappropriate for participation in the study as determined by the study team.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Group 1: SCC-ALIC

Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the subgenual cingulate cortex (SCC) at the first stimulation visit, then LTFUS is delivered to the anterior limb of the internal capsule (ALIC) at the second stimulation visit.

Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex

Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule

Experimentell: Group 2: ALIC-SCC

Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the anterior limb of the internal capsule (ALIC) at the first stimulation visit, then LTFUS is delivered to the subgenual cingulate cortex (SCC) at the second stimulation visit.

Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex

Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Modulation of SCC activity during SCC stimulation
Tidsram: Days 14, 21, 28

Functional MRI is used to quantify modulation of SCC activity during SCC stimulation

Days 14, 21, 28
Modulation of SCC activity during ALIC stimulation
Tidsram: Days 14, 21

Functional MRI is used to quantify modulation of SCC activity during ALIC stimulation

Days 14, 21
Study dropout
Tidsram: From enrollment to the end of participation at 7 weeks

Dropout or withdrawal due to stimulation-related adverse effects

From enrollment to the end of participation at 7 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
PANAS-X
Tidsram: Immediately before and after each LTFUS on Days 14, 21, 28

Positive and Negative Affect Schedule, Expanded Form

Immediately before and after each LTFUS on Days 14, 21, 28
MADRS
Tidsram: Days 14, 21, 28, 35, 49

Montgomery-Asberg Depression Rating Scale

Days 14, 21, 28, 35, 49
HDRS-6
Tidsram: Days 0, 14, 15, 21, 22, 28, 29, 35, 49

6-item Hamilton Depression Rating Scale

Days 0, 14, 15, 21, 22, 28, 29, 35, 49
IDS-SR
Tidsram: Days 0, 14, 21, 28, 35, 49

Inventory of Depressive Symptomatology, Self-Rated

Days 0, 14, 21, 28, 35, 49
GAD-7
Tidsram: Days 0, 14, 21, 28, 35, 49

7-item Generalized Anxiety Disorder Scale

Days 0, 14, 21, 28, 35, 49
YMRS
Tidsram: Days 0, 14, 15, 21, 22, 28, 29, 35, 49

Young Mania Rating Scale

Days 0, 14, 15, 21, 22, 28, 29, 35, 49
C-SSRS
Tidsram: Days 0, 14, 15, 21, 22, 28, 29, 35, 49

Columbia Suicide Severity Rating Scale, Screen Version

Days 0, 14, 15, 21, 22, 28, 29, 35, 49
GASE
Tidsram: Days 15, 22, 29

Generic Assessment of Side Effects scale

Days 15, 22, 29
MoCA
Tidsram: Days 14, 15, 49

Montreal Cognitive Assessment

Days 14, 15, 49

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Brian J Mickey, University of Utah

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 mars 2025

Primärt slutförande (Faktisk)

11 september 2026

Avslutad studie (Faktisk)

11 september 2026

Studieregistreringsdatum

Först inskickad

24 mars 2025

Först inskickad som uppfyllde QC-kriterierna

24 mars 2025

Första postat (Faktisk)

30 mars 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • IRB_00148802R61
  • R61MH134943 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera